E-viri
Recenzirano
-
Perrone, Salvatore; D'Elia, Gianna Maria; Annechini, Giorgia; Ferretti, Antonietta; Tosti, Maria Elena; Foà, Robin; Pulsoni, Alessandro
Leukemia research, 05/2016, Letnik: 44Journal Article
Highlights • The 10-year OS in SMZL was 95.1%: similar to survival of age-matched general population. • The IIL-Score calculated at diagnosis permitted to stratify patients into three groups of risk. • At 10 years, 30% of SMZL patients (N = 21) are still on Watch & Wait. • Splenectomy and rituximab +/− chemo showed similar results, but chemo was inferior.
